Literature DB >> 34035707

Current Use of Fecal Calprotectin in the Management of Patients With Inflammatory Bowel Disease.

Marc Ferrante1.   

Abstract

Entities:  

Year:  2020        PMID： 34035707      PMCID： PMC8132670     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  4 in total

Review 1.  The role and utility of faecal markers in inflammatory bowel disease.

Authors:  Frank S Lehmann; Emanuel Burri; Christoph Beglinger
Journal:  Therap Adv Gastroenterol       Date:  2015-01       Impact factor: 4.409

2.  Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.

Authors:  Geert D'Haens; Marc Ferrante; Severine Vermeire; Filip Baert; Maja Noman; Liesbeth Moortgat; Patricia Geens; Doreen Iwens; Isolde Aerden; Gert Van Assche; Gust Van Olmen; Paul Rutgeerts
Journal:  Inflamm Bowel Dis       Date:  2012-02-16       Impact factor: 5.325

Review 3.  Fecal calprotectin in inflammatory bowel disease.

Authors:  Natalie E Walsham; Roy A Sherwood
Journal:  Clin Exp Gastroenterol       Date:  2016-01-28

4.  Fecal calprotectin correlates with active colonic inflammatory bowel disease but not with small intestinal Crohn's disease activity.

Authors:  Eran Zittan; Orlaith B Kelly; Ian M Gralnek; Mark S Silverberg; A Hillary Steinhart
Journal:  JGH Open       Date:  2018-07-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.